GlassScriptPhysician profile
Caroline N Ford
NPI 1275295537
$6,212.47
in general payments reported to CMS, 2019-2025
34 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $2,540 · 2023: $2,201 · 2024: $1,141 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Education: $60.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.94 |
| Education | $60.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.42 | 2021-2025 | |
| Lilly USA, LLC | $752.78 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $576.63 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $538.50 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $379.00 | 2022-2024 | Shingrix, Nucala, Arexvy |
| Pfizer INC. | $324.71 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $310.07 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $292.69 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $283.38 | 2022-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $217.40 | 2022 | |
| Astellas Pharma US INC | $178.92 | 2022-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.17 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $143.81 | 2022-2024 | Belsomra, Gardasil, Capvaxive |
| Amgen INC. | $120.30 | 2022-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $101.23 | 2022-2024 | Spravato |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $88.28 | 2023 | Zio Xt Patch |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.71 | 2022-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $61.34 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $56.04 | 2022-2023 | |
| Lundbeck LLC | $55.20 | 2023-2024 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $51.88 | 2022-2024 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $48.20 | 2021-2023 | Trintellix |
| Sumitomo Pharma America, INC. | $41.12 | 2023-2024 | Gemtesa |
| Biogen, INC. | $22.13 | 2022 | |
| Galderma Laboratories, L.P. | $20.96 | 2025 | |
| Ethicon US, LLC | $20.40 | 2025 | Stratafix, Surgicel Nu-Knit, Dermabond Prineo |
| Novartis Pharmaceuticals Corporation | $18.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.43 | 2022 | |
| Smith+Nephew, INC. | $16.44 | 2024 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $15.60 | 2022 | |
| Motiva USA, LLC | $15.03 | 2025 | |
| Ironshore Pharmaceuticals INC. | $14.78 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.46 | 2023 | NP Thyroid 60 |
| Eisai INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.